Amendment: SEC Form SCHEDULE 13G/A filed by Prelude Therapeutics Incorporated
$PRLD
Biotechnology: Pharmaceutical Preparations
Health Care
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13G
|
UNDER THE SECURITIES EXCHANGE ACT OF 1934
|
(Amendment No. 5)
|
Prelude Therapeutics Inc (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
74065P101 (CUSIP Number) |
03/31/2025 (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
![]() |
![]() |
![]() |
SCHEDULE 13G
|
CUSIP No. | 74065P101 |
1 | Names of Reporting Persons
Vaddi Krishna | ||||||||
2 | Check the appropriate box if a member of a Group (see instructions)
![]() ![]() | ||||||||
3 | Sec Use Only | ||||||||
4 | Citizenship or Place of Organization
UNITED STATES
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
9 | Aggregate Amount Beneficially Owned by Each Reporting Person
6,397,839.00 | ||||||||
10 | Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
![]() | ||||||||
11 | Percent of class represented by amount in row (9)
13.8 % | ||||||||
12 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person: (1) The aggregate amount beneficially owned by the Reporting Person consists of (i) 4,728,081 shares of voting common stock beneficially owned directly by the Reporting Person, consisting of (a) 1,999,296 shares of voting common stock and (b) 2,728,785 shares of voting common stock underlying stock options that are exercisable within 60 days of March 31, 2025, (ii) 142,553 shares of voting common stock held by Sidus Ventures, LLC, (iii) 423,655 shares of voting common stock held by Dolphin City Trust, (iv) 551,776 shares of voting common stock held by Blue Sky Trust and (v) 551,774 shares of voting common stock held by Brocade Trust. The Reporting Person is the manager of Sidus Ventures, LLC and may be deemed to have beneficial ownership over the securities held by Sidus Ventures, LLC. The Reporting Person is the beneficiary of Dolphin City Trust and may be deemed to have beneficial ownership over the securities held by Dolphin City Trust. The Reporting Person is the investment advisor for each of the Blue Sky Trust and the Brocade Trust, and may be deemed to have beneficial ownership over the securities held by each of the Blue Sky Trust and the Brocade Trust.
(2) The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficially owned by the Reporting Person and an aggregate of 43,604,202 shares of voting common stock outstanding as of March 31, 2025, as reported by the Issuer to the Reporting Person, plus the number of shares underlying stock options held by the Reporting Person that are exercisable within 60 days of March 31, 2025, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person.
SCHEDULE 13G
|
Item 1. | ||
(a) | Name of issuer:
Prelude Therapeutics Inc | |
(b) | Address of issuer's principal executive offices:
175 INNOVATION BOULEVARD, WILMINGTON, Delaware, 19805 | |
Item 2. | ||
(a) | Name of person filing:
Krishna Vaddi (the "Reporting Person") | |
(b) | Address or principal business office or, if none, residence:
The address of the principal business office of the Reporting Person is:
c/o Prelude Therapeutics Incorporated
175 Innovation Boulevard
Wilmington, Delaware 19805 | |
(c) | Citizenship:
United States | |
(d) | Title of class of securities:
Common Stock, par value $0.0001 per share | |
(e) | CUSIP No.:
74065P101 | |
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |
(a) | ![]() | |
(b) | ![]() | |
(c) | ![]() | |
(d) | ![]() | |
(e) | ![]() | |
(f) | ![]() | |
(g) | ![]() | |
(h) | ![]() | |
(i) | ![]() | |
(j) | ![]() please specify the type of institution: | |
(k) | ![]() | |
Item 4. | Ownership | |
(a) | Amount beneficially owned:
See Row 9 of cover page for each Reporting Person. | |
(b) | Percent of class:
See Row 11 of cover page for each Reporting Person. | |
(c) | Number of shares as to which the person has:
| |
(i) Sole power to vote or to direct the vote:
See Row 5 of cover page for each Reporting Person. | ||
(ii) Shared power to vote or to direct the vote:
See Row 6 of cover page for each Reporting Person. | ||
(iii) Sole power to dispose or to direct the disposition of:
See Row 7 of cover page for each Reporting Person. | ||
(iv) Shared power to dispose or to direct the disposition of:
See Row 8 of cover page for each Reporting Person. | ||
Item 5. | Ownership of 5 Percent or Less of a Class. | |
Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. | |
Not Applicable
| ||
Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. | |
Not Applicable
| ||
Item 8. | Identification and Classification of Members of the Group. | |
Not Applicable
| ||
Item 9. | Notice of Dissolution of Group. | |
Not Applicable
|
Item 10. | Certifications: |
Not Applicable
|
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|